Amicus Therapeutics Inc. CEO John Crowley told BioWorld Today his firm won't be the only company working on a therapy for the rare skin disorder epidermolysis bullosa (EB), but the potential $847 million takeover of privately held Scioderm Inc. to bring aboard phase III Zorblisa means a handsome lead over the competition.